Trial Update: NCT05870579 Now Active, Not Recruiting (Phase 1)

A clinical trial update was recorded on August 20, 2026 for study NCT05870579. The trial, titled "[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer," is a Phase 1 study. Its current status is listed as active, not recruiting. This designation means the trial is ongoing but is no longer enrolling new participants. The study evaluates a combination regimen involving [177Lu]Lu-NeoB alongside ribociclib and fulvestrant in participants with ER-positive, HER2-negative, and GRPR-positive advanced breast cancer. No results or outcome data have been reported as part of this update. The record reflects only a change in recruitment and operational status of the trial as of the date noted. Gonadorelin, referenced in connection with this trial's broader research context, remains an approved compound. Readers interested in the study details, including its design and current phase, can consult the official trial listing for further specifics. For general background on gonadorelin as a compound, refer to the compound overview available on this platform.